Pembrolizumab Plus Lenvatinib in Second-Line and Third-Line Patients With Pleural Mesothelioma
Recommended
Pembrolizumab Plus Lenvatinib in Second-Line and Third-Line Patients With Pleural Mesothelioma
Researchers assessed the clinical activity of this combination therapy among patients with pleural mesothelioma who progressed after platinum-pemetrexed chemotherapy.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->